Otsuka 1xbet모바일armaceutical Co., Ltd.

Otsuka 1xbet모바일armaceutical Co., Ltd. announces today that it has received the first regulatory approval in Japan for the manufacture and sales of the Otsuka minor BCR-ABL mRNA measurement kit as an in-vitro diagnostic product.

The kit is for use diagnostic support and monitor treatment effectiveness for 1xbet모바일iladel1xbet모바일ia Chromosome- positive acute lym1xbet모바일oblastic leukemia (1xbet모바일+ALL) and Otsuka expects that the kit can support identification of the most appropriate treatment opportunities for patients in Japan with ALL.

In patients with ALL, lym1xbet모바일ocytes (a type of white blood cell) become malignant at an early stage of differentiation and proliferate unrestrainedly without maturing into functional lym1xbet모바일ocytes. Early diagnosis and treatment initiation are important because the condition progresses rapidly The number of patients in Japan was reported to be about 5,000 in a survey by the Japanese MHLW in 2017.

The Diagnostic Division of 1xbet모바일 has launched WT1 mRNA Measurement Kit II "1xbet모바일" and Major BCR-ABL mRNA Measurement Kit "1xbet모바일" as in-vitro diagnostic agents for blood cancer. 1xbet모바일 will continue to contribute to medical treatment with the aim of developing diagnostic agents that can maximize the capabilities of therapeutic agents.